Skip to main content

Table 2 Percent survival by year and diagnosis after IL-2

From: Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

Year

1

2

3

4

5

Melanoma

59

41

31

24

23

Renal cancer

75

56

44

39

31

Back to article page